Automated Smoking Cessation for People Living With HIV

Palo Alto (17 mi)

Overseen byDamon J Vidrine, Dr.PH

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: N/A

Waitlist Available

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial is testing if an automated system can help people quit smoking more effectively than traditional methods that require more resources.

Eligibility Criteria

This trial is for people living with HIV who currently smoke more than 5 cigarettes a day, have smoked at least 100 in their lifetime, and are ready to quit within a week of joining. Participants must own a smartphone compatible with the study app, speak English or Spanish, and have an email address. Pregnant or breastfeeding individuals, those on cessation meds or in another smoking study can't join.

Exclusion Criteria

I am currently using medication to help me stop smoking.

Treatment Details

The study is testing if an Automated Video-Assisted Smoking Treatment using smartphones helps people stop smoking better than Standard Treatment that requires more resources. It involves nicotine patches, lozenges, counseling, and automated treatment delivered through a smartphone.

2Treatment groups

Experimental Treatment

Active Control

Group I: Automated TreatmentExperimental Treatment3 Interventions

Participants randomized to Automated Treatment (AT) will be given a 10-week supply of nicotine patches and lozenges. AT will also comprise of: 1) 12 proactive treatment videos, delivered weekly, that are tailored on smoking status, motivation, agency, and/or negative affect/stress; 2) 26 weeks of on-demand access to treatment content; 3) 26 weeks of text content

Group II: Standard TreatmentActive Control3 Interventions

Participants randomized to Standard Treatment (ST) will be provided with a 10-week supply of nicotine patches and lozenges. ST participants will be connected with their state's tobacco quitline services and will complete weekly 4-item smartphone assessments electronically for 26 weeks. The weekly assessments consist of questions on smoking status, motivation, self-efficacy, and perceived stress.

Nicotine lozenge is already approved in United States, Canada, European Union for the following indications:

🇺🇸 Approved in United States as Nicorette Lozenge for: